Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01898494 · ClinicalTrials.gov registry record · Phase 2

Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer

A Phase 2 study of Human Papilloma Virus Infection and Stage III Squamous Cell Carcinoma of the Oropharynx, sponsored by ECOG-ACRIN Cancer Research Group.

Active
Registry status
Phase 2
Development phase
519
Enrollment target
20
Study locations

NCT01898494 is a Phase 2 study of Human Papilloma Virus Infection and Stage III Squamous Cell Carcinoma of the Oropharynx that is active but no longer recruiting, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 519 participants, below the 1,299-participant average among 4 other Human Papilloma Virus Infection trials with a reported enrollment target (60% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01898494, a Phase 2 study of Human Papilloma Virus Infection and Stage III Squamous Cell Carcinoma of the Oropharynx, is active but no longer recruiting, sponsored by ECOG-ACRIN Cancer Research Group.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
519 participants
Enrollment target
20
Study locations

Study Summary

This randomized phase II trial studies how well transoral surgery followed by low-dose or standard-dose radiation therapy works in treating patients with human papilloma virus (HPV) positive stage III-IVA oropharyngeal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy with chemotherapy may kill any tumor cells that remain after surgery. It is not yet known how much extra treatment needs to be given after surgery.

Conditions Studied

Human Papilloma Virus Infection Stage III Squamous Cell Carcinoma of the Oropharynx Stage IVA Squamous Cell Carcinoma of the Oropharynx Stage IVB Squamous Cell Carcinoma of the Oropharynx

Interventions

  • DRUG cisplatin
  • DRUG carboplatin
  • RADIATION intensity-modulated radiation therapy
  • PROCEDURE Transoral surgery

Study Locations (20)

California

  • City of Hope Comprehensive Cancer Center - Duarte
  • UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
  • Kaiser Permanente Oakland-Broadway - Oakland
  • Stanford Cancer Institute - Palo Alto
  • UCSF Medical Center-Mount Zion - San Francisco

Colorado

  • Rocky Mountain Cancer Centers-Boulder - Boulder
  • Penrose-Saint Francis Healthcare - Colorado Springs
  • Rocky Mountain Cancer Centers-Penrose - Colorado Springs
  • Porter Adventist Hospital - Denver

Florida

  • University of Miami Sylvester Comprehensive Cancer Center at Deerfield Beach - Deerfield Beach
  • University of Miami Miller School of Medicine-Sylvester Cancer Center - Miami
  • Florida Hospital Orlando - Orlando

Georgia

  • Emory University Hospital Midtown - Atlanta
  • Emory University/Winship Cancer Institute - Atlanta

Alabama

  • University of Alabama at Birmingham Cancer Center - Birmingham

Arizona

  • Mayo Clinic in Arizona - Scottsdale

Arkansas

  • University of Arkansas for Medical Sciences - Little Rock

Connecticut

  • Yale University - New Haven

Trial Details

FieldValue
Enrollment Target 519 participants
Start Date 2014-01-22
Est. Completion 2026-12
Phase Phase 2

Sponsor

ECOG-ACRIN Cancer Research Group

75 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01898494

The ClinicalTrials.gov registry entry for NCT01898494 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 519 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,299-participant average among 4 other Human Papilloma Virus Infection trials with a reported enrollment target (60% lower). The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 75 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Human Papilloma Virus Infection appearing as the primary indexed condition, and to 4 interventions - of which cisplatin is the first listed.

NCT01898494 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Colorado, Florida.

Frequently Asked Questions

What is clinical trial NCT01898494 about?

NCT01898494 is a clinical study titled "Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer". This randomized phase II trial studies how well transoral surgery followed by low-dose or standard-dose radiation therapy works in treating patients with human papilloma virus (HPV) positive stage III-IVA oropharyngeal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used...

What is the current status of trial NCT01898494?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 519 participants. The study started on 2014-01-22. Estimated completion is 2026-12.

What conditions does trial NCT01898494 study?

This clinical trial studies the following conditions: Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx.

What interventions are being tested in trial NCT01898494?

The interventions under investigation include: cisplatin (DRUG), carboplatin (DRUG), intensity-modulated radiation therapy (RADIATION), Transoral surgery (PROCEDURE).

Who is sponsoring clinical trial NCT01898494?

This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01898494 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Human Papilloma Virus Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Human Papilloma Virus Infection

All registered trials for this condition

Stage III Squamous Cell Carcinoma of the Oropharynx

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.